A biomarker-based blood testing system for predicting and managing impending rheumatoid arthritis flares

This technology uses blood tests to detect specific RNA, protein markers, and unique cells that predict rheumatoid arthritis flares up to two weeks before symptoms, enabling early intervention and improved disease management through minimally invasive sampling.

Background

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent inflammation of the joints, leading to pain, swelling, and eventual joint destruction. A hallmark of RA is its unpredictable pattern of disease activity, with patients experiencing sudden flares—periods of acute inflammation and worsening symptoms—interspersed with periods of relative remission. Despite advances in therapeutic options, including NSAIDs, steroids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents, the management of RA remains challenging. This is largely due to the inability to anticipate flares before they occur, which limits the effectiveness of timely intervention and often results in irreversible joint damage and reduced quality of life. There is a critical need for reliable biomarkers that can predict impending flares, enabling clinicians to intervene earlier and tailor treatment to prevent or mitigate disease exacerbations.

Current approaches to RA management primarily rely on clinical assessment and patient-reported symptoms, which only detect flares after inflammation has already begun. Laboratory tests such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and autoantibody titers provide general information about inflammation or disease presence but lack the specificity and temporal resolution needed to predict flares in advance. Imaging modalities like ultrasound and MRI can detect joint inflammation but are impractical for frequent monitoring and do not offer predictive value for future flares. Furthermore, existing biomarkers are often influenced by factors unrelated to RA activity, leading to false positives or negatives. As a result, most patients experience flares without warning, and clinicians are forced to react rather than prevent disease progression, underscoring the urgent need for more precise and predictive tools in RA management.

Technology

This technology enables the early prediction and management of rheumatoid arthritis (RA) flares by detecting specific molecular and cellular biomarkers in peripheral blood, often before any clinical symptoms are apparent. The system relies on two temporally distinct sets of markers: AC2 markers, which are associated with naïve B cell and leukocyte pathways and appear about two weeks before a flare, and AC3 markers, which are linked to mesenchymal and fibroblast pathways and emerge roughly one week prior to flare onset. A central feature is the identification of Pre-Inflammatory Mesenchymal (PRIME) cells—CD45-CD31-PDPN+ (optionally IL17RD+) cells—which increase in circulation ahead of a flare and can be detected using flow cytometry. The technology employs minimally invasive blood collection, such as fingerstick sampling, and utilizes RT-PCR, RNA sequencing, or antibody-based assays to quantify these markers, providing actionable information for preemptive therapeutic intervention with standard or targeted RA treatments.

What differentiates this technology is its ability to forecast RA flares with high specificity and sensitivity by integrating both molecular and cellular signals that precede clinical manifestations. Unlike conventional RA management tools, which rely on patient-reported symptoms or general inflammatory markers that only rise after a flare has begun, this approach identifies predictive changes in the immune system and stromal cell populations days to weeks in advance. The inclusion of PRIME cells as a novel, mechanistically relevant biomarker bridges the gap between systemic immune activity and local joint inflammation, offering a unique window for intervention. The system’s compatibility with home-based, minimally invasive sampling and its comprehensive marker panels enable personalized, timely adjustments to therapy, potentially reducing flare severity, improving patient quality of life, and setting a new standard for proactive autoimmune disease management.

Benefits

  • Enables prediction of rheumatoid arthritis flares 1–2 weeks before clinical symptoms appear
  • Uses minimally invasive blood sampling, including fingerstick collection, for patient-friendly monitoring
  • Identifies specific RNA, protein, and cellular biomarkers (AC2, AC3 markers and PRIME cells) for accurate flare forecasting
  • Supports early, personalized therapeutic intervention to prevent or mitigate flare severity
  • Facilitates use of standard and targeted RA treatments guided by biomarker status
  • Provides validated diagnostic kits and protocols suitable for clinical and home use
  • Improves disease management and patient outcomes through proactive flare monitoring
  • Offers potential applicability to other autoimmune diseases with flare-remission patterns

Applications

  • RA flare prediction diagnostics
  • Home-based RA monitoring kits
  • Preemptive RA therapy guidance
  • Clinical decision support for rheumatologists
  • Targeted RA drug development

Additional info

This technology identifies RNA, protein, and cellular biomarkers in peripheral blood to predict rheumatoid arthritis flares. It monitors AC2 markers (B cell pathways, 14 days pre-flare) and AC3 markers (fibroblast pathways, 7 days pre-flare) alongside circulating CD45-CD31-PDPN+ Pre-Inflammatory Mesenchymal (PRIME) cells. Using RT-PCR or flow cytometry on fingerstick samples, the system enables preemptive treatment with biologics or standard medications, improving clinical management through early detection.